1312755-47-7 Usage
Molecular weight
254.27 g/mol The mass of one mole of the compound, based on the atomic weights of its constituent elements.
Appearance
White crystalline solid The physical form and color of the compound.
Melting point
198-200°C The temperature range at which the compound transitions from a solid to a liquid state.
Solubility
Slightly soluble in water, soluble in organic solvents such as methanol, ethanol, and acetonitrile The compound's ability to dissolve in different solvents.
Spectroscopic data
1H NMR, 13C NMR, and IR spectra are available for the compound Spectroscopic techniques used to identify and study the structure of the compound.
Derivative of pyrrolo[2,3-b]pyridine-3-carboxylic acid
The compound is derived from pyrrolo[2,3-b]pyridine-3-carboxylic acid, with modifications to its structure.
Fluorine substitution at the 5-position
A fluorine atom is attached to the 5th position of the pyrrolopyridine ring, altering the compound's properties and reactivity.
Potential applications
Pharmaceutical research and development, synthesis of novel drugs The compound may be used in the creation of new drugs and pharmaceutical compounds.
Building block for new drugs
The compound may serve as a starting point for the development of new drugs or pharmaceutical compounds, due to its unique structure and properties.
Check Digit Verification of cas no
The CAS Registry Mumber 1312755-47-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,2,7,5 and 5 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1312755-47:
(9*1)+(8*3)+(7*1)+(6*2)+(5*7)+(4*5)+(3*5)+(2*4)+(1*7)=137
137 % 10 = 7
So 1312755-47-7 is a valid CAS Registry Number.
1312755-47-7Relevant articles and documents
1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER
-
, (2011/07/07)
The invention relates to 1, 7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk 1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
